AR008389A1 - Derivados peptidicos - Google Patents
Derivados peptidicosInfo
- Publication number
- AR008389A1 AR008389A1 ARP970102498A ARP970102498A AR008389A1 AR 008389 A1 AR008389 A1 AR 008389A1 AR P970102498 A ARP970102498 A AR P970102498A AR P970102498 A ARP970102498 A AR P970102498A AR 008389 A1 AR008389 A1 AR 008389A1
- Authority
- AR
- Argentina
- Prior art keywords
- derivatives
- peptide derivatives
- treatment
- pharmaceutical
- new peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/851—Placenta; amniotic fluid
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Trata de derivados peptídicos, utiles para uso farmacéutico, de formula (I), P-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-Q, donde P, AA1, AA2, AA3, AA4, AA5,AA6, AA7, AA8 y Q poseen diferentes significados definidos en el presente contexto, y sus sales aceptables para uso farmacéutico, y de composicionesfarmacéuticas que contienen dichos derivados. Los nuevos derivados peptídicos son valiosos para el tratamiento de enfermedades inflamatorias o autoinmunesmediadas por células T dependientes delMHC clase II, tal como la artritis reumatoidea. Trata, además, de los procesos para la elaboracion de los nuevosderivados peptídicos y del uso de los compuestos en el tratamiento clínico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9611881.5A GB9611881D0 (en) | 1996-06-07 | 1996-06-07 | Peptide derivatives |
GBGB9622890.3A GB9622890D0 (en) | 1996-11-02 | 1996-11-02 | Peptide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR008389A1 true AR008389A1 (es) | 2000-01-19 |
Family
ID=26309459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970102498A AR008389A1 (es) | 1996-06-07 | 1997-06-06 | Derivados peptidicos |
Country Status (21)
Country | Link |
---|---|
US (2) | US6541453B2 (es) |
EP (1) | EP0914333B1 (es) |
JP (1) | JP2000512277A (es) |
KR (1) | KR100451522B1 (es) |
CN (1) | CN1130372C (es) |
AR (1) | AR008389A1 (es) |
AT (1) | ATE283278T1 (es) |
AU (1) | AU727757B2 (es) |
BR (1) | BR9709533A (es) |
CA (1) | CA2252417A1 (es) |
DE (1) | DE69731747T2 (es) |
HR (1) | HRP970308B1 (es) |
ID (1) | ID17440A (es) |
IL (1) | IL127332A0 (es) |
NO (1) | NO985680L (es) |
NZ (1) | NZ332347A (es) |
PL (1) | PL330348A1 (es) |
SK (1) | SK166798A3 (es) |
TR (1) | TR199802537T2 (es) |
TW (1) | TW474947B (es) |
WO (1) | WO1997046578A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9809021D0 (en) * | 1998-04-29 | 1998-06-24 | Zeneca Ltd | Chemical process |
KR20020047245A (ko) * | 1999-10-18 | 2002-06-21 | 에프.지.엠. 헤르만스 ; 이.에이치. 리링크 | 면역요법에 사용하기 위한 수정 펩티드 및 펩티드모방체 |
JP2008188285A (ja) * | 2007-02-06 | 2008-08-21 | Bridgestone Corp | バックパッド及び車両用シート |
CN102186883B (zh) * | 2008-09-18 | 2016-08-03 | 西北大学 | Nmda受体调节剂和其用途 |
US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
AU2011215704B2 (en) | 2010-02-11 | 2015-07-23 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | 2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도 |
SG11201505860XA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
US9738650B2 (en) | 2013-01-29 | 2017-08-22 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
EP2951182B1 (en) | 2013-01-29 | 2020-03-18 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
JP2016506962A (ja) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系nmda受容体モジュレーターおよびその使用 |
KR20150110787A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
PE20190174A1 (es) | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
CA3031539C (en) | 2016-08-01 | 2023-11-28 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
SG11201900558RA (en) | 2016-08-01 | 2019-02-27 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
ES2979128T3 (es) | 2016-08-01 | 2024-09-24 | Tenacia Biotechnology Hong Kong Co Ltd | Moduladores del receptor NMDA espirolactama y bis-espirolactama y uso de los mismos |
SG10202101055VA (en) | 2016-08-01 | 2021-03-30 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and uses thereof |
CA3089561A1 (en) | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
CN109115899A (zh) * | 2018-06-19 | 2019-01-01 | 南京肽业生物科技有限公司 | 一种Fmoc氨基酸的分析方法 |
US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
EP4141110A1 (en) | 2020-04-24 | 2023-03-01 | Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" | Method for producing particles of bacteriophages of the genus levivirus |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4254107A (en) | 1979-11-27 | 1981-03-03 | Merck & Co., Inc. | Long-lasting agonists of enkephalin |
US4301151A (en) | 1979-11-27 | 1981-11-17 | Merck & Co., Inc. | Long-lasting agonists of enkephalin |
US4474778A (en) | 1983-11-09 | 1984-10-02 | E. R. Squibb & Sons, Inc. | Lactam containing compounds, their pharmaceutical compositions and method of use |
US4680283A (en) | 1984-09-26 | 1987-07-14 | Merck & Co., Inc. | Analogs of substance P and eledoisin |
DE3711335A1 (de) | 1987-04-03 | 1988-10-20 | Merck Patent Gmbh | Aminosaeurederivate |
US5331089A (en) | 1988-03-25 | 1994-07-19 | Merck Sharpe & Dohme, Ltd. | Peptides useful as tachykinin agonists |
EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
WO1990003399A1 (en) * | 1988-09-30 | 1990-04-05 | Australian Commercial Research & Development Limited | Amino acid transport proteins, amino acid analogues, assay apparatus, uses thereof for treatment and diagnosis of cancer |
US5223485A (en) | 1989-01-31 | 1993-06-29 | Abbott Laboratories | Anaphylatoxin-receptor ligands |
AU8305491A (en) | 1990-08-01 | 1992-03-02 | Cytel Corporation | Novel immunosuppressant peptides |
DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
WO1993005011A1 (en) | 1991-08-29 | 1993-03-18 | Sandoz Ltd. | Novel immunosuppressants |
JPH0725887A (ja) | 1993-06-04 | 1995-01-27 | Sterling Winthrop Inc | インターロイキン−1β転換酵素阻害剤 |
ATE415173T1 (de) | 1993-09-14 | 2008-12-15 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
WO1995026980A2 (en) * | 1994-04-01 | 1995-10-12 | Immulogic Pharmaceutical Corporation | Haptenated peptides and uses thereof |
ATE206433T1 (de) | 1995-03-24 | 2001-10-15 | Molecumetics Ltd | Beta-schleifenähnliche verbindungen und deren verwendung als protease-inhibitoren |
US5840835A (en) | 1995-10-30 | 1998-11-24 | Merck & Co., Inc. | Inhibitors of peptide binding to MHC class II proteins |
US5719296A (en) | 1995-10-30 | 1998-02-17 | Merck & Co., Inc. | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins |
US5817757A (en) | 1995-10-30 | 1998-10-06 | Merck & Co., Inc. | Inhibitors of peptide binding to MHO class II proteins |
AU7604196A (en) | 1995-10-30 | 1997-05-22 | Merck & Co., Inc. | Novel inhibitors of peptide binding to mhc class ii proteins |
GB9702377D0 (en) * | 1996-02-23 | 1997-03-26 | Zeneca Ltd | Peptide derivatives |
GB9621836D0 (en) | 1996-10-19 | 1996-12-11 | Zeneca Ltd | Peptide compounds |
GB9625865D0 (en) | 1996-12-12 | 1997-01-29 | Zeneca Ltd | Peptides |
-
1997
- 1997-06-03 WO PCT/GB1997/001491 patent/WO1997046578A1/en active IP Right Grant
- 1997-06-03 US US09/202,077 patent/US6541453B2/en not_active Expired - Fee Related
- 1997-06-03 PL PL97330348A patent/PL330348A1/xx unknown
- 1997-06-03 JP JP10500312A patent/JP2000512277A/ja not_active Ceased
- 1997-06-03 SK SK1667-98A patent/SK166798A3/sk unknown
- 1997-06-03 IL IL12733297A patent/IL127332A0/xx unknown
- 1997-06-03 TR TR1998/02537T patent/TR199802537T2/xx unknown
- 1997-06-03 CN CN97195216A patent/CN1130372C/zh not_active Expired - Fee Related
- 1997-06-03 NZ NZ332347A patent/NZ332347A/xx unknown
- 1997-06-03 AT AT97924156T patent/ATE283278T1/de not_active IP Right Cessation
- 1997-06-03 EP EP97924156A patent/EP0914333B1/en not_active Expired - Lifetime
- 1997-06-03 DE DE69731747T patent/DE69731747T2/de not_active Expired - Fee Related
- 1997-06-03 AU AU29720/97A patent/AU727757B2/en not_active Ceased
- 1997-06-03 KR KR10-1998-0710049A patent/KR100451522B1/ko not_active IP Right Cessation
- 1997-06-03 BR BR9709533A patent/BR9709533A/pt not_active Application Discontinuation
- 1997-06-03 CA CA002252417A patent/CA2252417A1/en not_active Abandoned
- 1997-06-04 HR HR970308A patent/HRP970308B1/xx not_active IP Right Cessation
- 1997-06-06 ID IDP971947A patent/ID17440A/id unknown
- 1997-06-06 AR ARP970102498A patent/AR008389A1/es unknown
- 1997-06-06 TW TW086107849A patent/TW474947B/zh not_active IP Right Cessation
-
1998
- 1998-12-04 NO NO985680A patent/NO985680L/no not_active Application Discontinuation
-
2002
- 2002-12-16 US US10/319,512 patent/US20030195158A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HRP970308A2 (en) | 1998-04-30 |
NZ332347A (en) | 2000-05-26 |
EP0914333B1 (en) | 2004-11-24 |
DE69731747T2 (de) | 2006-02-02 |
CN1130372C (zh) | 2003-12-10 |
KR20000016465A (ko) | 2000-03-25 |
NO985680D0 (no) | 1998-12-04 |
TR199802537T2 (xx) | 1999-03-22 |
ID17440A (id) | 1997-12-24 |
US6541453B2 (en) | 2003-04-01 |
SK166798A3 (en) | 1999-07-12 |
NO985680L (no) | 1999-02-04 |
ATE283278T1 (de) | 2004-12-15 |
DE69731747D1 (de) | 2004-12-30 |
BR9709533A (pt) | 1999-08-10 |
AU2972097A (en) | 1998-01-05 |
TW474947B (en) | 2002-02-01 |
US20020103335A1 (en) | 2002-08-01 |
US20030195158A1 (en) | 2003-10-16 |
EP0914333A1 (en) | 1999-05-12 |
AU727757B2 (en) | 2000-12-21 |
CA2252417A1 (en) | 1997-12-11 |
WO1997046578A1 (en) | 1997-12-11 |
HRP970308B1 (en) | 2002-04-30 |
PL330348A1 (en) | 1999-05-10 |
IL127332A0 (en) | 1999-09-22 |
KR100451522B1 (ko) | 2004-12-08 |
CN1221424A (zh) | 1999-06-30 |
JP2000512277A (ja) | 2000-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR008389A1 (es) | Derivados peptidicos | |
CL2018003348A1 (es) | Péptidos y combinación de péptidos y andamiajes novedosos para su uso en inmunoterapia contra carninoma de células renales (rcc) y otros canceres. (divisional solicitud 201702448) | |
Low et al. | Chemical characterization of thymosin beta 4. | |
ES2193145T3 (es) | Proteinas procoagulants quimericas. | |
CY1109649T1 (el) | Αντιγονα και συνθεσεις απο neisseria | |
ES2190432T3 (es) | Activacion in vitro de celulas t citotoxicas. | |
ES2195664T3 (es) | Uso de fumaratos de dialquilo. | |
AR010348A1 (es) | Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen | |
AR001288A1 (es) | Anticuerpos monoclonales de monos especificos paraB7, 1 Y/O B7,2 humano, sus formas primatizadas, composiciones farmaceuticas con anticuerpos y su uso como inmunosupresores. | |
CO4600637A1 (es) | Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata | |
CY1115885T1 (el) | Αντιστρεπτα πεγκυλιωμενα (pegylated) φαρμακα | |
DE69739497D1 (de) | Menschlische Telomerase katalytische Untereinheit | |
UY25246A1 (es) | Imidazotriazinonas sustituidas por 2-fenilo | |
DE60327786D1 (de) | Kdr-peptide und diese enthaltende impfstoffe | |
ATE286128T1 (de) | Conotoxine | |
GT199900150A (es) | 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas. | |
ATE271058T1 (de) | Mycophenol bisphosponatverbindungen | |
CY1109710T1 (el) | Επιτοπα βοηθητικων τ λεμφοκυτταρων | |
AR041067A1 (es) | Formulacion estable de un anticuerpo modificado con el ph optimizado | |
AR018201A1 (es) | Compuesto de mesilato de n-(3-etinilfenil)-6,7-bis-(2-metoxietoxi)-4-quinazolinamina, composiciones que los contienen y su uso de dichos compuestos para la preparacion de medicamentos. | |
ES2169356T3 (es) | Procedimiento para la preparacion de nitrobifenileno. | |
AR031924A1 (es) | Anticuerpos anti-cd28 silenciados y el uso de estos | |
DE60231986D1 (de) | Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose | |
CU23228A1 (es) | Fragmentos de anticuerpos especificos para el antigeno carcinoembrionario humano (cea) secuencias de sus regiones variables y vectores para la expresion microbiana de los mismos | |
EP0235064A3 (en) | Aromatic compounds with amide structure, derivatives of amino-benzoic acids, hydroxybenzoic acids, cinnamic acids, urocanic acids and benzimidazoles, absorbing uvb and/or uva |